Choices for long-term hypertensive control in patients after first-ever hemorrhagic stroke: a nationwide cohort study.


Background:To compare the long-term clinical outcomes of different antihypertensive drugs in stable patients after acute hemorrhagic stroke (HS). Methods:From January 2001 to December 2013, patients with first-ever primary HS were identified in the National Health Insurance Research Database, Taiwan. Patients with traumatic intracerebral hemorrhage and secondary HS were excluded. Those with first-ever HS were recruited and classified into three groups: (1) angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB); (2) calcium channel blocker (CCB); and (3) other antihypertensive drugs (comparison) groups. Propensity score matching was used to balance the distribution of baseline characteristics, stroke severity, and medications between any two of the three groups. A validation study was performed using the databank of the Stroke Registry in Chang-Gung Healthcare System to reduce the bias. Primary outcomes were recurrent HS, ischemic stroke, any stroke, and all-cause mortality. Results:Compared to the comparison group, the ACEI/ARB group [35.4% versus 39.3%; hazard ratio (HR), 0.84; 95% confidence interval (CI), 0.74-0.95] and CCB group (33.0% versus 41.9%; HR, 0.72; 95% CI, 0.64-0.81) had a lower risk of all-cause mortality during long-term follow up. The CCB group had a similar risk of all-cause mortality to the ACEI/ARB group. Risks of recurrent HS, ischemic stroke, or any stroke were not different between the study groups. Conclusions:Antihypertensive drug class could be important to long-term outcomes in HS patients in addition to the target control of blood pressure. Both ACEIs/ARBs and CCBs are associated with lower risks of all-cause mortality. Our results may be applied to inform future research on hypertensive control in HS patients.


Ther Adv Neurol Disord


Liu CH,Lin YS,Chi CC,Liou CW,Lee JD,Peng TI,Lee TH




Has Abstract


2018-09-28 00:00:00












  • Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.

    abstract:BACKGROUND:The aim of this study was to analyse registry data of seizure outcome and adverse events (AEs) for perampanel as add-on therapy in patients with focal epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in patients ⩾12 years. METHOD:A retrospective 2-year chart review of all patie...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Rohracher A,Kalss G,Leitinger M,Granbichler C,Deak I,Dobesberger J,Kuchukhidze G,Thomschewski A,Höfler J,Trinka E

    更新日期:2016-11-01 00:00:00

  • Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials.

    abstract:Background:Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache. Objective:To p...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Gklinos P,Mitsikostas DD

    更新日期:2020-04-28 00:00:00

  • Web-based interventions in multiple sclerosis: the potential of tele-rehabilitation.

    abstract::The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Tallner A,Pfeifer K,Mäurer M

    更新日期:2016-07-01 00:00:00

  • Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience.

    abstract::Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reduction in the accumulation of disability and slowing of the brain volume loss that occurs from the earliest stages of the disease. Teriflunomide, a once-daily, oral immunomodulatory therapy, has demonstrated efficacy across...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Miller AE

    更新日期:2017-12-01 00:00:00

  • The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

    abstract::B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and production of autoantibodies directed against myelin. Hence, the usage of B-cell-depleting monoclonal antibodies as therapy for autoimmune...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Sorensen PS,Blinkenberg M

    更新日期:2016-01-01 00:00:00

  • Vascular medicine and thrombectomy in stroke.

    abstract::The treatment of stroke caused by intracranial vessel occlusion with intravenous recombinant tissue plasminogen activator (rt-PA) was the only evidence-based treatment option for a long time. Nevertheless the response rate was disappointing in large vessel occlusions. Five studies that evaluated the efficacy of mechan...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Fischer S,Weber W

    更新日期:2017-11-22 00:00:00

  • Erythropoietin: still on the neuroprotection road.

    abstract::Acute stroke is one of the major causes of death and disabilities. Since the 1980s many clinical studies have been conducted to evaluate neuroprotective approaches to treat this important brain vascular event. However, to date the only drug approved (recombinant tissue plasminogen activator [rtPA]) represents a thromb...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Subirós N,Del Barco DG,Coro-Antich RM

    更新日期:2012-05-01 00:00:00

  • Best practice in the use of natalizumab in multiple sclerosis.

    abstract::Natalizumab is approved for the treatment of patients with relapsing-remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. The drug has proved highly effective, both in a clinical trial setting and in clinical practice, with ma...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Fernández O

    更新日期:2013-03-01 00:00:00

  • Multimodal MRI characteristics of the glioblastoma infiltration beyond contrast enhancement.

    abstract::Our inability to identify the invasive margin of glioblastomas hampers attempts to achieve local control. Diffusion tensor imaging (DTI) has been implemented clinically to delineate the margin of the tumor infiltration, its derived anisotropic (q) values can extend beyond the contrast-enhanced area and correlates clos...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Yan JL,Li C,Boonzaier NR,Fountain DM,Larkin TJ,Matys T,van der Hoorn A,Price SJ

    更新日期:2019-05-14 00:00:00

  • Longitudinal cortical network reorganization in early relapsing-remitting multiple sclerosis.

    abstract:Background:Network science provides powerful access to essential organizational principles of the brain. The aim of this study was to investigate longitudinal evolution of gray matter networks in early relapsing-remitting MS (RRMS) compared with healthy controls (HCs) and contrast network dynamics with conventional atr...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Fleischer V,Koirala N,Droby A,Gracien RM,Deichmann R,Ziemann U,Meuth SG,Muthuraman M,Zipp F,Groppa S

    更新日期:2019-04-24 00:00:00

  • Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

    abstract::For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone. Treating aggressive forms...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Awad A,Stüve O

    更新日期:2009-11-01 00:00:00

  • Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.

    abstract::The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every other day (early t...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Freedman MS

    更新日期:2014-11-01 00:00:00

  • Advances in spinal muscular atrophy therapeutics.

    abstract::Spinal muscular atrophy (SMA) is a progressive, recessively inherited neuromuscular disease, characterized by the degeneration of lower motor neurons in the spinal cord and brainstem, which leads to weakness and muscle atrophy. SMA currently represents the most common genetic cause of infant death. SMA is caused by th...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Parente V,Corti S

    更新日期:2018-02-05 00:00:00

  • Capsaicinoids in the treatment of neuropathic pain: a review.

    abstract::The treatment of neuropathic pain is difficult. Oral pharmaceuticals have significant side effects, and treatment efficacy tends to be modest. The use of topical analgesics reduces the potential for systemic side effects and allows direct application of medications to the area of pain. The natural spicy substance, cap...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Peppin JF,Pappagallo M

    更新日期:2014-01-01 00:00:00

  • Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis.

    abstract:OBJECTIVES:The cumulative safety and efficacy measures of percutaneous transluminal angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-analytical approach. METHODS:We conducted a systematic ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Tsivgoulis G,Katsanos AH,Magoufis G,Kargiotis O,Papadimitropoulos G,Vadikolias K,Karapanayiotides T,Ellul J,Alexandrov AW,Mitsias PD,Alexandrov AV

    更新日期:2016-09-01 00:00:00

  • Paradoxical association of symptomatic cerebral edema with local hypoperfusion caused by the 'watershed shift' after revascularization surgery for adult moyamoya disease: a case report.

    abstract::Superficial temporal artery-middle cerebral artery anastomosis is generally considered as an effective method in improving damage associated with intracerebral occlusions in moyamoya disease. Hemodynamic changes caused by revascularization are the cause of many postoperative complications. Of the 186 consecutive surge...

    journal_title:Therapeutic advances in neurological disorders



    authors: Yu J,Hu M,Yi L,Zhou K,Zhang J,Chen J

    更新日期:2019-09-25 00:00:00

  • Therapy with cladribine is efficient and safe in patients previously treated with natalizumab.

    abstract:Background:The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML). Recently, new therapeutic options have become available for pati...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Möhn N,Skripuletz T,Sühs KW,Menck S,Voß E,Stangel M

    更新日期:2019-12-02 00:00:00

  • Efficacy and safety of laquinimod in multiple sclerosis: current status.

    abstract::Laquinimod is a novel immunomodulatory agent, in development as a potential disease-modifying treatment for multiple sclerosis (MS). Structurally related to linomide, its pharmacological predecessor, laquinimod combines anti-inflammatory and possibly clinically relevant neuroprotective effects with the convenience of ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Haggiag S,Ruggieri S,Gasperini C

    更新日期:2013-11-01 00:00:00

  • Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.

    abstract:OBJECTIVES:To assess clinical outcomes and patient satisfaction in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were switched from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG). METHODS:Eight consecutive patients, four...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Hadden RD,Marreno F

    更新日期:2015-01-01 00:00:00

  • Application of immunotherapy for neurological manifestations in hypermobile Ehlers-Danlos syndrome.

    abstract::Ehlers-Danlos syndrome (EDS) is a heterogeneous heritable connective tissue disorder with various neurological manifestations, including chronic pain. The neurological manifestations in EDS are often regarded as being caused by the associated musculoskeletal disorders or polyneuropathy. Here, we present two patients w...

    journal_title:Therapeutic advances in neurological disorders



    authors: Araki M,Lin Y,Ono H,Sato W,Yamamura T

    更新日期:2018-08-18 00:00:00

  • Implementation of computer-based language therapy in aphasia.

    abstract::A first step in evaluating the use of computers in language therapy for individuals with aphasia is to establish the treatment as active in small groups prior to large-scale clinical trials. The present study evaluated a comprehensive computer-based language therapy program in a group of eight individuals with chronic...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Archibald LM,Orange JB,Jamieson DJ

    更新日期:2009-09-01 00:00:00

  • Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord.

    abstract::Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

    journal_title:Therapeutic advances in neurological disorders



    authors: Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

    更新日期:2020-06-03 00:00:00

  • Botulinum toxin in the management of chronic migraine: clinical evidence and experience.

    abstract::Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Escher CM,Paracka L,Dressler D,Kollewe K

    更新日期:2017-02-01 00:00:00

  • C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis.

    abstract:Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

    更新日期:2020-08-10 00:00:00

  • Hypothalamic deep brain stimulation in the treatment of chronic cluster headache.

    abstract::Cluster headache (CH) is a short-lasting unilateral headache associated with ipsilateral craniofacial autonomic manifestations. A positron emission tomography (PET) study has shown that the posterior hypothalamus is activated during CH attacks, suggesting that hypothalamic hyperactivity plays a key role in CH pathophy...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Leone M,Franzini A,Cecchini AP,Broggi G,Bussone G

    更新日期:2010-05-01 00:00:00

  • Advances in imaging of brain abnormalities in neuromuscular disease.

    abstract::Brain atrophy, white matter abnormalities, and ventricular enlargement have been described in different neuromuscular diseases (NMDs). We aimed to provide a comprehensive overview of the substantial advancement of brain imaging in neuromuscular diseases by consulting the main libraries (Pubmed, Scopus and Google Schol...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Angelini C,Pinzan E

    更新日期:2019-05-06 00:00:00

  • The role of erenumab in the treatment of migraine.

    abstract::Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of migraine symptoms, migraine-specific quality of life and headache re...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Andreou AP,Fuccaro M,Lambru G

    更新日期:2020-05-27 00:00:00

  • A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures.

    abstract::Topiramate has been widely utilized worldwide as an effective medication against partial- and generalized-onset seizures. Extended-release topiramate was developed to provide patients with the convenience of once-daily dosing and potentially improved tolerability by reducing serum concentration fluctuation. USL255 is ...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章,评审


    authors: Chung SS

    更新日期:2015-05-01 00:00:00

  • Wernicke-Korsakoff syndrome associated with mtDNA disease.

    abstract:Introduction:Wernicke encephalopathy (WE) and Wernicke-Korsakoff syndrome (WKS) are well-known disorders caused by thiamine deficiency. In addition to the classical concept of these diseases, some literature data suggest a connection between mitochondrial dysfunction and WE/WKS. Psychotic disorders and WKS seem to run ...

    journal_title:Therapeutic advances in neurological disorders



    authors: Jimoh IJ,Sebe B,Balicza P,Fedor M,Pataky I,Rudas G,Gal A,Inczedy-Farkas G,Nemeth G,Molnar MJ

    更新日期:2020-07-30 00:00:00

  • Effective and safe diet therapies for Lennox-Gastaut syndrome with mitochondrial dysfunction.

    abstract:Background:Lennox-Gastaut syndrome (LGS) is a typical intractable form of epilepsy that most often occurs between the second and sixth year of life. This study aimed to evaluate the clinical efficacy and safety of ketogenic diet therapies (DTs) for LGS with mitochondrial dysfunction. Methods:This was a retrospective s...

    journal_title:Therapeutic advances in neurological disorders

    pub_type: 杂志文章


    authors: Na JH,Kim HD,Lee YM

    更新日期:2020-02-06 00:00:00